References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffects of an intensive communications strategies on postmenopausal osteoporosis awareness in women
Tellier, V; Ben Sedrine, Wafa ULg; Gosset, Christiane ULg et al

in Arthritis and Rheumatism (1999), 42(S1), 356

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailComparison of four markers of bone resorption as diagnostic or monitoring tools in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Taquet, AN; Christiansen, C et al

in Arthritis and Rheumatism (1999), 42(S1), 291

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailInterest of a simple pre-screening test for optimazing the cost/benefit value of bone densitometry
Ben Sedrine, Wafa ULg; Broers, P; Brands, G et al

in Arthritis and Rheumatism (1999), 42(S1), 289

Detailed reference viewed: 5 (2 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fractures in patients with low femoral neck bone mineral density
Miller, P; Roux, C; McClung, M et al

in Arthritis and Rheumatism (1999), 42(S1), 287

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailQuality of life in patients with vertebral fractures : validation of the quality of life questionnaire of the European Foundation for Osteoporosis. (QUALEFFO)
Lips, P; Cooper, C; Agnusdei, D et al

in Osteoporosis International (1999), 10

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailThe influence of tissular cross-talking on osteoarthritis progression: role of non steroidal antiinflammatory drugs
Pelletier, JP; Reginster, Jean-Yves ULg

in Osteoarthritis and Cartilage (1999), 7

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of drugs intended for use in the treatment of male osteoporosis
Kaufman, JM; Compston, J; Audran, MA et al

in Calcified Tissue International (1999), 65

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailRisedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose-response study
Brown, JP; Hosking, DJ; Ste-Marie, LG et al

in Calcified Tissue International (1999), 64

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailFluoride for the treatment of osteoporosis
Reginster, Jean-Yves ULg

in Annals of Internal Medicine (1999), 130

Detailed reference viewed: 3 (0 ULg)
See detailIn vitro models for the study of cartilage damage and repair
Henrotin, Yves ULg; Reginster, Jean-Yves ULg

in Reginster, Jean-Yves; Pelletier, J-P; Martel-Pelletier, J (Eds.) et al Osteoarthritis: Clinical and experimental aspects (1999)

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailDirect costs of hip fractures in patients over 60 years of age in Belgium.
Reginster, Jean-Yves ULg; Gillet, Philippe ULg; Ben Sedrine, Wafa ULg et al

in PharmacoEconomics (1999), 15(5), 507-514

OBJECTIVE: Osteoporosis-related costs are now considered a major burden for health authorities in most developed countries. An accurate and exhaustive evaluation of these costs would be a major ... [more ▼]

OBJECTIVE: Osteoporosis-related costs are now considered a major burden for health authorities in most developed countries. An accurate and exhaustive evaluation of these costs would be a major contribution to health economic studies evaluating the efficiency of screening and prevention strategies. Osteoporosis is the most frequent underlying cause of femoral neck fractures in the elderly; these fractures weigh heavily on healthcare budgets. However, in Belgium, very few data on the financial burden of hip fractures are available and no updated estimates have been made. The goal of this paper is to estimate the direct medical expenditures associated with hip fractures in Belgium in 1996. DESIGN AND SETTING: This 1-year population-based cross-sectional study is conducted from the social security perspective. The target population in this study are men and women aged 60 years and over. PATIENTS AND PARTICIPANTS: We selected patients who had been hospitalised for a hip fracture during the year 1996 who were also affiliated with a registered social security organisation (covering 25% of the Belgian population). The sample constituted 2374 patients. INTERVENTIONS: For each of these patients, we collected an exhaustive and detailed list of healthcare resource use as well as nursing home admissions following the hip fracture event. Cost items investigated in the analysis were inpatient hospital costs and outpatient costs. Mean annual costs per case recorded in the sample were then extrapolated to the whole country on the basis of an exhaustive list of diagnoses having lead to all countrywide hospitalisations (1,700,000 hospital stays/year). MAIN OUTCOME MEASURES AND RESULTS: The mean hospital inpatient costs for hip fracture were evaluated at 332,148 Belgian francs (BeF) [$US8977] per case and BeF4,367,746,200 ($US118,047,194) for the whole country (10 million inhabitants). Patients with a hip fracture experienced an annual BeF27,825 ($US752) extra outpatient cost during the year following this fracture event, after correcting for costs related to additional comorbidity already present before the hip fracture. Finally, after a proximal femoral neck fracture, the rate of nursing home admission was higher, both for men and women at any age compared with age- and gender-matched population. CONCLUSIONS: With a total cost (acute hospital and outpatient costs) of BeF4,667,894,950 ($US126,159,323) per year in Belgium, proximal femoral neck fracture should be considered a major health economic problem and appropriate measures to prevent this disease should be rapidly undertaken. [less ▲]

Detailed reference viewed: 64 (15 ULg)
Full Text
Peer Reviewed
See detailEffects of Nimesulide and Sodium Diclofenac on Interleukin-6, Interleukin-8, Proteoglycans and Prostaglandin E2 Production by Human Articular Chondrocytes in Vitro
Henrotin, Yves ULg; Labasse, A. H.; Simonis, P. E. et al

in Clinical and Experimental Rheumatology (1999), 17(2), 151-60

OBJECTIVES: The aim of this study was to investigate the effects of two nonsteroidal anti-inflammatory drugs (NSAIDs), nimesulide and sodium diclofenac, on the production of proteoglycans (PG ... [more ▼]

OBJECTIVES: The aim of this study was to investigate the effects of two nonsteroidal anti-inflammatory drugs (NSAIDs), nimesulide and sodium diclofenac, on the production of proteoglycans (PG), prostaglandin E2 (PGE2) and cytokines (IL-6 and IL-8) by human articular chondrocytes in vitro. METHODS: Enzymatically isolated chondrocytes were cultured under constant agitation in a well defined culture medium. Specific radioimmunoassays were used to quantify PG and PGE2 production. Cytokine production (IL-6 and IL-8) was assayed by enzyme amplified sensitivity immunoassays (EASIAs). RESULTS: At a concentration of 3 micrograms/ml, nimesulide did not affect the PG production by chondrocytes. This concentration was superior to the highest level of nimesulide found in the synovial fluid of patients with rheumatoid arthritis 3 hours after the last oral administration of nimesulide (100 mg twice daily for 7 days). At 6 micrograms/ml a significant reduction in the PG content was obtained in the cellular phase in 5 out of the 8 cultures investigated. No similar effect was observed in the culture supernatants. Above this concentration nimesulide inhibited PG production in a dose-dependent manner. At concentrations ranging from 0.005 to 1 microgram/ml diclofenac did not significantly alter PG production. At therapeutic concentrations PGE2 production was totally inhibited by nimesulide, thus suggesting that PG inhibition is not linked to PGE2 production. Nimesulide inhibited PGE2 production by unstimulated (IC50 = 6 ng/ml) and IL-1 beta-stimulated (IC50 = 6.9 ng/ml) chondrocytes. At these concentrations, PGE2 production was fully inhibited by diclofenac. Furthermore, both nimesulide and diclofenac at therapeutic concentrations significantly decreased spontaneous and IL-1 beta-stimulated IL-6 production by human chondrocytes, but did not modify IL-8 production. CONCLUSION: From the results of this study we conclude that nimesulide and diclofenac at therapeutic concentrations are potent inhibitors of PGE2 and IL-6 production while they do not modify proteoglycan or IL-8 production. [less ▲]

Detailed reference viewed: 16 (6 ULg)
Full Text
Peer Reviewed
See detailEffects of Nimesulide and Indometacin on Cox-1 and Cox-2: A Comparative Study
de Leval, X.; Dogné, Jean-Michel ULg; Neven, P. et al

in Journal de Pharmacie de Belgique (1999), 54(3), 89-90

Evidence of the existence of two forms of cyclooxygenases and the clinical relevance of COX-2 inhibition led to the development of COX-2 selective NSAIDs. In order to evaluate this selectivity, we have ... [more ▼]

Evidence of the existence of two forms of cyclooxygenases and the clinical relevance of COX-2 inhibition led to the development of COX-2 selective NSAIDs. In order to evaluate this selectivity, we have developed and validated an enzymatic method. The precision and reproducibility of the assay were determined and COX-2 selectivity examined using nimesulide and indometacin. [less ▲]

Detailed reference viewed: 16 (6 ULg)
Peer Reviewed
See detailDepressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women.
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Paul, I. et al

in Maturitas (1999), 33(2), 133-7

Major depression has been repeatedly but not consistently reported to be associated with low bone mineral density (BMD) and to an increased risk for fracture in women. We have investigated, in healthy ... [more ▼]

Major depression has been repeatedly but not consistently reported to be associated with low bone mineral density (BMD) and to an increased risk for fracture in women. We have investigated, in healthy postmenopausal women, whether depressive symptomatology, assessed by the General Health Questionnaire (GHQ), was associated to a significant decrease in BMD, hence supporting the hypothesis of an independent pathogenetic link between the two disorders. We investigated 121 postmenopausal women, aged 48-77 years, spontaneously attending a screening visit for osteoporosis in an outpatient facility. BMD of the spine and the non-dominant hip (total and neck areas) were measured by Dual Energy X-Ray absorptiometry. All subjects completed to the 'General Health Questionnaire' translated and validated in French. No significant correlations were observed between the GHQ score and BMD of the spine (P = 0.54), the total hip area (P = 0.65), or the femoral neck area (P = 0.65). No differences in terms of spinal or femoral BMD were observed between women with GHQ score < 5 or > or = 5. When comparing values of BMD between women within the upper and the lower quartiles for GHQ score, no difference was observed for spine (P = 0.69), total hip (P = 0.80), or femoral neck (P = 0.93). Similarly, GHQ scores were not significantly different when comparing women in the upper and lower quartiles of BMD distribution at the spine or the hip. In conclusion, notwithstanding the clinical pattern of postmenopausal osteoporosis can lead to depression and, on the other hand, hormonal and behavioral disturbances reported in depression might be enhancing factors for accelerated bone loss, our present results do not support the hypothesis that otherwise healthy postmenopausal women with increased depressive complaints are also more prone to exhibit osteoporotic fractures. [less ▲]

Detailed reference viewed: 17 (4 ULg)
See detailEtude pilote : Case management intégré dans les hôpitaux belges.
de Froidmont, C.; Dejace, Alain ULg; Englebert, L. et al

Report (1999)

Detailed reference viewed: 24 (6 ULg)
See detailEstablished postmenopausal osteoporosis – Assessment of treatment options
Reginster, Jean-Yves ULg; Halkin, V.; Fraikin, G. et al

in Menopause Review (1999), 1(IV), 39-55

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailProphylactic Use of Alfacalcidol in Corticosteroid-Induced Osteoporosis
Reginster, Jean-Yves ULg; Kuntz, D.; Verdickt, W. et al

in Osteoporosis International (1999), 9(1), 75-81

One hundred and forty-five patients suffering from diseases requiring long-term treatment with high doses of corticosteroids (30 mg/day or greater of prednisolone) were recruited to the study. Patients ... [more ▼]

One hundred and forty-five patients suffering from diseases requiring long-term treatment with high doses of corticosteroids (30 mg/day or greater of prednisolone) were recruited to the study. Patients had to be steroid naive on entry to the study (not more than 15 days of treatment with a corticosteroid within the previous 24 months). Patients were randomized to receive either 1 microgram/day alfacalcidol or placebo capsules for 12 months. Bone mineral density (BMD) of the lumbar spine was assessed by dual-photon absorptiometry on entry and after 3, 6 and 12 months' treatment. Safety was monitored by the recording of all adverse events reported by patients and the regular screening of blood samples for hematology and serum biochemistry. Of the 145 patients, 74 were randomized to alfacalcidol and 71 to placebo. The treatment groups were well matched at baseline with no significant differences in demographic, clinical or biochemical parameters. The mean equivalent dose of prednisolone at baseline was 46.6 mg/day and 46.3 mg/day for the alfacalcidol and placebo group respectively. From the 145 patients randomized to treatment, 71 (38 who received alfacalcidol and 33 who received placebo) provided BMD data both at baseline and at 3, 6 and 12 months. The percentage change in BMD after 6 months' treatment was -2.11% in the alfacalcidol group and -4.00% in the placebo group (p = 0.39). After 12 months the percentage change in BMD was +0.39% (CI: -4.28 to 4.81) in the alfacalcidol group and -5.67% (CI: -8.13 to -3.21) in the placebo group, this difference (6.06%, CI: 0.88 to 11.24) being statistically significant (p = 0.02). An intention to treat analysis also showed a significant difference between the two treatment groups in alfacalcidol's favor (3.81%, p = 0.01; CI: 0.92 to 6.70). There was no significant difference between the two treatment groups in the corticosteroid dose at any time point during the study. Serum calcium was measured throughout and there were no significant differences between the two treatment groups at any visit. This study suggests that alfacalcidol can prevent corticosteroid-induced bone loss from the lumbar spine. Long-term use of alfacalcidol was not associated with any significant adverse effects in this diverse group of patients. [less ▲]

Detailed reference viewed: 31 (1 ULg)